Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free AHG Stock Alerts

Akso Health Group (AHG) Financials

Akso Health Group logo
$2.05 -0.15 (-6.82%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$2.06 +0.01 (+0.49%)
As of 07:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Akso Health Group

Annual Income Statements for Akso Health Group

This table shows Akso Health Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 3.54 8.57 65 5.53 -71 -35 -17 -1.36 -9.46 -135
Consolidated Net Income / (Loss)		 3.54 8.57 66 5.53 -71 -35 -17 -1.25 -9.52 -135
Net Income / (Loss) Continuing Operations		 3.54 8.57 66 -7.62 -47 -4.29 -4.10 -13 -9.12 -135
Total Pre-Tax Income 		4.17 10 77 -6.81 -47 -4.29 -4.01 -13 -9.09 -166
Total Operating Income		 4.14 9.91 76 -7.19 -48 -4.24 -3.26 -14 -8.64 -166
Total Gross Profit		 12 18 99 3.70 6.91 0.00 0.61 1.27 0.12 -0.28
Total Revenue		 12 23 107 3.70 6.96 0.00 6.00 13 2.41 15
Operating Revenue		 12 23 107 3.70 6.96 0.00 6.00 13 2.41 15
Total Cost of Revenue		 0.00 5.15 8.50 0.00 0.04 0.00 5.39 12 2.29 15
Operating Cost of Revenue		 - 5.15 8.50 0.00 0.04 0.00 5.39 12 2.29 15
Total Operating Expenses		 7.75 7.86 23 11 55 2.09 3.06 16 8.76 166
Selling, General & Admin Expense		 1.55 2.65 5.82 3.13 20 2.03 2.67 16 8.59 3.64
Marketing Expense		 3.84 5.21 15 1.17 1.46 0.00 0.00 0.01 0.17 0.00
Impairment Charge		 - - - 0.00 29 - - 0.00 0.00 162
Total Other Income / (Expense), net		 0.03 0.18 1.32 0.38 1.23 -2.21 -1.55 1.20 -0.45 0.03
Other Income / (Expense), net		 0.03 0.18 1.32 0.38 1.23 -0.05 -0.75 1.20 -0.45 0.03
Income Tax Expense		 0.63 1.52 11 0.81 0.49 0.00 0.09 0.02 0.02 -31
Net Income / (Loss) Discontinued Operations		 - - - 13 -24 -31 -13 12 -0.40 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.00 0.00 0.03 - 0.00 0.00 0.00 0.11 -0.06 -0.49
Basic Earnings per Share		 $0.08 $0.20 $1.46 $0.11 ($1.46) ($0.71) ($0.28) ($0.02) ($0.07) ($0.16)
Weighted Average Basic Shares Outstanding		 42.08M 42.33M 44.98M 48.69M 48.76M 48.84M 59.61M 68.60M 141.52M 855.29M
Diluted Earnings per Share		 $0.08 $0.20 $1.37 $0.10 ($1.46) ($0.71) ($0.28) ($0.02) ($0.07) ($0.16)
Weighted Average Diluted Shares Outstanding		 42.08M 42.33M 47.66M 52.91M 48.76M 48.84M 59.61M 68.60M 141.52M 855.29M
Weighted Average Basic & Diluted Shares Outstanding		 - - 47.96M 49.20M 48.82M 48.85M 68.60M 68.60M 437.17M 1.66B

Quarterly Income Statements for Akso Health Group

No quarterly income statements for Akso Health Group are available.

Annual Cash Flow Statements for Akso Health Group

This table details how cash moves in and out of Akso Health Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025
Net Change in Cash & Equivalents		 6.86 11 113 -75 25 4.20 6.80 -13 77 90
Net Cash From Operating Activities		 7.03 8.19 88 -1.73 -58 10 -8.63 -3.25 1.35 1.18
Net Cash From Continuing Operating Activities		 7.03 8.19 88 1.12 -35 -7.60 -11 -5.98 0.71 1.18
Net Income / (Loss) Continuing Operations		 3.54 8.57 66 -7.62 -47 -4.29 -4.10 -13 -9.12 -135
Depreciation Expense		 0.06 0.09 0.17 0.02 0.12 - - 0.00 0.00 2.15
Non-Cash Adjustments To Reconcile Net Income		 0.00 0.00 1.83 7.67 41 -3.11 0.39 8.27 7.77 162
Changes in Operating Assets and Liabilities, net		 3.43 -0.47 20 1.05 -29 -0.20 -7.57 -1.17 2.06 -28
Net Cash From Discontinued Operating Activities		 - - - -2.85 -23 18 2.65 2.73 0.65 0.00
Net Cash From Investing Activities		 -0.12 -0.29 -28 -68 13 -0.00 -20 18 -55 -106
Net Cash From Continuing Investing Activities		 -0.12 -0.29 -28 -67 17 0.00 -20 18 -55 -106
Purchase of Property, Plant & Equipment		 -0.12 -0.29 -0.46 -0.01 -0.20 - - 0.00 0.00 -0.15
Acquisitions		 - - - - - - - 0.00 -56 -94
Other Investing Activities, net		 0.00 0.00 -27 -51 32 0.00 -20 18 1.53 -12
Net Cash From Discontinued Investing Activities		 - - - -1.00 -4.60 -0.00 0.04 0.00 0.00 0.00
Net Cash From Financing Activities		 0.24 4.29 48 -0.03 -1.55 -9.04 35 -28 132 196
Net Cash From Continuing Financing Activities		 0.24 4.29 48 51 -8.21 4.63 9.10 -28 132 196
Repayment of Debt		 -10 2.29 4.35 51 0.00 4.63 -0.91 -28 -7.69 0.00
Issuance of Common Equity		 0.00 2.00 48 - 0.00 0.00 10 0.00 139 196
Net Cash From Discontinued Financing Activities		 - - - -51 6.65 -14 26 0.00 0.00 0.00
Effect of Exchange Rate Changes		 -0.28 -0.78 5.77 -5.38 - - 0.61 -0.44 -1.27 -1.12
Cash Interest Paid		 - - - 0.00 2.41 - 0.68 0.34 0.11 0.00
Cash Income Taxes Paid		 0.00 0.30 1.02 12 3.21 2.11 0.09 0.02 0.02 0.00

Quarterly Cash Flow Statements for Akso Health Group

No quarterly cash flow statements for Akso Health Group are available.

Annual Balance Sheets for Akso Health Group

This table presents Akso Health Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025
Total Assets		 28 164 173 80 32 63 20 142 215
Total Current Assets		 23 163 98 52 30 63 20 142 196
Cash & Equivalents		 19 133 57 6.67 15 18 7.92 85 176
Accounts Receivable		 - 0.00 0.42 24 8.90 20 9.23 0.00 13
Inventories, net		 - - - - 0.00 7.80 1.69 0.19 0.19
Prepaid Expenses		 4.14 1.25 3.33 0.43 0.60 0.18 0.27 57 6.81
Plant, Property, & Equipment, net		 0.43 0.77 1.25 0.09 0.07 0.00 0.00 0.00 0.02
Total Noncurrent Assets		 4.58 0.00 74 28 1.50 0.00 0.00 0.00 19
Goodwill		 - - - - - - - 0.00 11
Intangible Assets		 - - - - - - - 0.00 7.88
Other Noncurrent Operating Assets		 4.18 - 0.00 0.67 - - - 0.00 0.10
Total Liabilities & Shareholders' Equity		 28 164 173 80 32 63 20 142 215
Total Liabilities		 4.88 24 47 32 14 51 12 3.59 16
Total Current Liabilities		 0.79 24 27 12 14 51 12 3.59 14
Accounts Payable		 0.79 - - 3.24 4.11 0.23 0.94 1.10 1.52
Current Deferred Revenue		 - 0.00 0.11 - - - 0.19 0.42 10
Current Deferred & Payable Income Tax Liabilities		 - 20 9.37 - 0.30 0.09 0.10 0.07 0.03
Other Current Liabilities		 - 0.00 14 0.74 - 37 9.69 2.00 2.04
Total Noncurrent Liabilities		 4.09 0.00 20 20 0.00 0.00 0.00 0.00 1.99
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - 0.00 1.95
Other Noncurrent Operating Liabilities		 4.09 0.00 0.00 0.01 - - - 0.00 0.04
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 24 140 127 48 17 12 8.84 138 199
Total Preferred & Common Equity		 24 140 127 48 17 12 8.73 138 199
Total Common Equity		 24 140 127 48 17 12 8.73 138 199
Common Stock		 13 58 60 61 61 71 71 210 406
Retained Earnings		 12 77 70 -1.43 -36 -53 -54 -64 -199
Treasury Stock		 - 0.00 -1.32 -3.99 -3.99 -3.99 -3.99 -3.99 -3.99
Accumulated Other Comprehensive Income / (Loss)		 -1.54 4.38 -1.76 -7.05 -3.10 -1.65 -3.85 -4.09 -3.77
Noncontrolling Interest		 - - - - 0.00 0.00 0.11 0.06 0.03

Quarterly Balance Sheets for Akso Health Group

No quarterly balance sheets for Akso Health Group are available.

Annual Metrics And Ratios for Akso Health Group

This table displays calculated financial ratios and metrics derived from Akso Health Group's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025
DEI Shares Outstanding		 0.00 0.00 47,958,550.00 49,204,083.00 48,818,340.00 48,850,574.00 68,598,050.00 68,598,050.00 - 437,170,960.00
DEI Adjusted Shares Outstanding		 0.00 0.00 15,986,183.00 16,401,361.00 16,272,780.00 48,850,574.00 68,598,050.00 68,598,050.00 - 437,170,960.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 4.10 0.34 -4.38 -0.71 -0.25 -0.02 - -0.31
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 92.70% 367.96% -96.55% 88.33% -100.00% 0.00% 119.69% -81.68% 512.08%
EBITDA Growth		 0.00% 140.90% 659.64% -108.78% -588.48% 90.82% 6.64% -225.99% 30.42% -1,705.15%
EBIT Growth		 0.00% 142.23% 664.85% -108.82% -588.50% 90.84% 6.64% -225.99% 30.42% -1,728.80%
NOPAT Growth		 0.00% 139.42% 671.46% -107.75% -569.14% 91.18% 23.12% -337.57% 39.45% -1,825.26%
Net Income Growth		 0.00% 142.22% 664.34% -91.55% -1,386.89% 51.08% 51.62% 92.60% -662.90% -1,323.51%
EPS Growth		 0.00% 150.00% 585.00% -91.55% -1,386.89% 51.37% 60.56% 92.86% -250.00% -128.57%
Operating Cash Flow Growth		 0.00% 16.57% 971.13% -101.97% -3,266.62% 117.26% -185.78% 62.29% 141.53% -12.88%
Free Cash Flow Firm Growth		 0.00% 0.00% 1,390.39% -190.54% 44.39% 230.71% -52.28% -202.04% -198.09% -45.84%
Invested Capital Growth		 0.00% 0.00% 73.70% 686.21% -4.39% -78.23% -178.61% 102.82% 19,682.44% -56.96%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 77.53% 92.08% 100.00% 99.35% 0.00% 10.09% 9.63% 5.06% -1.91%
EBITDA Margin		 35.55% 44.44% 72.14% -183.77% -671.80% 0.00% -66.80% -99.13% -376.57% -1,110.59%
Operating Margin		 34.81% 43.25% 70.74% -194.55% -691.24% 0.00% -54.34% -108.23% -357.78% -1,125.37%
EBIT Margin		 35.03% 44.04% 71.97% -184.24% -673.53% 0.00% -66.80% -99.13% -376.57% -1,125.14%
Profit (Net Income) Margin		 29.75% 37.39% 61.08% 149.72% -1,023.06% 0.00% -280.83% -9.46% -394.17% -916.71%
Tax Burden Percent		 84.92% 84.92% 85.59% -81.27% 151.89% 811.19% 420.37% 9.55% 104.67% 81.48%
Interest Burden Percent		 100.00% 100.00% 99.14% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 15.08% 15.08% 14.41% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 394.11% 1,110.86% -15.31% -59.01% 0.00% -175.77% 0.00% -22.60% -305.66%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 392.53% 1,110.12% -25.83% 65.07% 0.00% -67.71% 0.00% -15.19% -291.08%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -321.18% -1,030.75% 19.46% -22.54% 0.00% 61.76% 0.00% 9.67% 225.40%
Return on Equity (ROE)		 0.00% 72.93% 80.11% 4.15% -81.55% -106.55% -114.01% -11.81% -12.92% -80.26%
Cash Return on Invested Capital (CROIC)		 0.00% 194.11% 1,057.01% -170.17% -54.53% 119.75% 0.00% -7,356.40% -220.58% -226.03%
Operating Return on Assets (OROA)		 0.00% 35.56% 80.30% -4.04% -36.95% 0.00% -8.48% -31.38% -11.19% -93.16%
Return on Assets (ROA)		 0.00% 30.20% 68.14% 3.28% -56.12% 0.00% -35.66% -3.00% -11.71% -75.90%
Return on Common Equity (ROCE)		 0.00% 72.93% 80.11% 4.15% -81.55% -106.55% -114.01% -11.74% -12.91% -80.24%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 36.47% 46.78% 4.37% -148.02% -201.64% -137.17% 0.00% -6.88% 0.00%
Net Operating Profit after Tax (NOPAT)		 3.52 8.42 65 -5.03 -34 -2.97 -2.28 -9.99 -6.05 -116
NOPAT Margin		 29.56% 36.73% 60.55% -136.19% -483.87% 0.00% -38.04% -75.76% -250.45% -787.76%
Net Nonoperating Expense Percent (NNEP)		 0.00% 1.59% 0.75% 10.52% -124.08% 2,497.27% -108.07% 57.49% -7.40% -14.58%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -112.98% - -58.45%
Cost of Revenue to Revenue		 0.00% 22.47% 7.92% 0.00% 0.65% 0.00% 89.91% 90.37% 94.94% 101.91%
SG&A Expenses to Revenue		 13.07% 11.54% 5.42% 84.75% 294.41% 0.00% 44.50% 117.81% 355.86% 24.64%
R&D to Revenue		 19.83% 0.00% 0.00% 0.00% 14.84% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 65.19% 34.28% 21.34% 294.55% 790.59% 0.00% 51.02% 117.86% 362.84% 1,123.46%
Earnings before Interest and Taxes (EBIT)		 4.17 10 77 -6.81 -47 -4.29 -4.01 -13 -9.09 -166
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 4.23 10 77 -6.79 -47 -4.29 -4.01 -13 -9.09 -164
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.42 0.14 0.55 2.24 0.93 0.19 0.86
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.42 0.14 0.55 2.24 0.93 0.19 0.95
Price to Revenue (P/Rev)		 0.00 0.00 0.00 14.45 0.99 0.00 4.59 0.62 10.99 11.64
Price to Earnings (P/E)		 0.00 0.00 0.00 9.65 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 3.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 10.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.33 0.36 0.00 1.14 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 2.68 0.00 1.52 0.02 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.44 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.11 0.47 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.16 0.42 0.58 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.16 0.42 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.82 -0.93 -0.75 -0.35 0.04 -0.91 -1.44 -0.64 -0.77
Leverage Ratio		 0.00 1.21 1.18 1.26 1.45 1.72 3.20 3.94 1.10 1.06
Compound Leverage Factor		 0.00 1.21 1.17 1.26 1.45 1.72 3.20 3.94 1.10 1.06
Debt to Total Capital		 0.00% 0.00% 0.00% 13.65% 29.37% 36.67% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 36.67% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 13.65% 29.37% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 1.29% 0.04% 0.02%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 86.35% 70.63% 63.33% 99.98% 98.71% 99.96% 99.98%
Debt to EBITDA		 0.00 0.00 0.00 -2.95 -0.43 -2.33 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 10.04 -0.25 1.19 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -2.95 -0.43 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 -3.97 -0.59 -3.37 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 13.54 -0.35 1.73 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -3.97 -0.59 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 1.63 -1.14 -1.06 -0.74 -4.25 4.77 3.77
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.55% 0.12% 0.03%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 29.62 6.84 3.68 4.21 2.09 1.24 1.76 39.52 14.20
Quick Ratio		 0.00 24.37 6.79 3.55 3.47 2.05 0.76 1.48 23.70 13.69
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 4.15 62 -56 -31 41 19 -20 -59 -86
Operating Cash Flow to CapEx		 5,832.13% 2,845.98% 19,236.24% -102,491.12% -30,267.59% 0.00% 0.00% 0.00% 0.00% 762.12%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 18.88 24.13 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 4.67 -10.73 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 4.67 -10.73 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.81 1.12 0.02 0.05 0.00 0.13 0.32 0.03 0.08
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.58 0.00 0.42 0.90 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.51 2.44 78.96
Fixed Asset Turnover		 0.00 53.56 179.51 3.66 10.34 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 6.53 0.00 0.00 0.00 0.00 2.49 20.46 2.24 11.47
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 630.15 0.00 879.08 404.64 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 145.27 149.49 4.62
Days Payable Outstanding (DPO)		 0.00 55.94 0.00 0.00 0.00 0.00 146.72 17.84 162.70 31.83
Cash Conversion Cycle (CCC)		 0.00 -55.94 0.00 0.00 630.15 0.00 732.36 532.06 -13.21 -27.21
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 4.27 7.42 58 56 12 -9.55 0.27 53 23
Invested Capital Turnover		 0.00 10.73 18.35 0.11 0.12 0.00 4.62 -2.84 0.09 0.39
Increase / (Decrease) in Invested Capital		 0.00 4.27 3.15 51 -2.56 -44 -22 9.82 53 -30
Enterprise Value (EV)		 0.00 0.00 0.00 -15 19 4.42 9.09 0.31 -59 -4.24
Market Capitalization		 0.00 0.00 0.00 53 6.89 9.55 28 8.12 27 172
Book Value per Share		 $0.00 $0.56 $3.11 $2.64 $0.98 $0.35 $0.25 $0.13 $2.02 $0.46
Tangible Book Value per Share		 $0.00 $0.56 $3.11 $2.64 $0.98 $0.35 $0.25 $0.13 $2.02 $0.41
Total Capital		 0.00 24 140 147 68 27 12 8.84 138 199
Total Debt		 0.00 0.00 0.00 20 20 10 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 20 20 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -19 -133 -68 12 -5.13 -18 -7.92 -85 -176
Capital Expenditures (CapEx)		 0.12 0.29 0.46 0.00 0.19 0.00 0.00 0.00 0.00 0.15
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 3.35 6.65 14 33 11 -6.14 0.92 53 6.08
Debt-free Net Working Capital (DFNWC)		 0.00 23 139 71 40 26 12 8.84 138 182
Net Working Capital (NWC)		 0.00 23 139 71 40 16 12 8.84 138 182
Net Nonoperating Expense (NNE)		 -0.02 -0.15 -0.57 -11 38 32 15 -8.74 3.47 19
Net Nonoperating Obligations (NNO)		 0.00 -19 -133 -68 7.68 -5.13 -22 -8.57 -85 -176
Total Depreciation and Amortization (D&A)		 0.06 0.09 0.17 0.02 0.12 0.00 0.00 0.00 0.00 2.15
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 14.62% 6.20% 371.99% 474.01% 0.00% -102.41% 6.94% 2,205.58% 41.16%
Debt-free Net Working Capital to Revenue		 0.00% 98.53% 129.85% 1,924.59% 569.83% 0.00% 204.76% 67.06% 5,733.42% 1,233.69%
Net Working Capital to Revenue		 0.00% 98.53% 129.85% 1,924.59% 569.83% 0.00% 204.76% 67.06% 5,733.42% 1,233.69%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $4.38 $0.33 ($4.38) ($0.71) ($0.28) ($0.02) ($0.07) ($0.16)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 14.99M 16.23M 16.25M 48.84M 59.61M 68.60M 141.52M 855.29M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $4.11 $0.30 ($4.38) ($0.71) ($0.28) ($0.02) ($0.07) ($0.16)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 15.89M 17.64M 16.25M 48.84M 59.61M 68.60M 141.52M 855.29M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 15.99M 16.40M 16.27M 48.85M 68.60M 68.60M 437.17M 1.66B
Normalized Net Operating Profit after Tax (NOPAT)		 3.52 8.42 65 -5.03 -13 -2.93 -2.01 -9.99 -6.05 -2.75
Normalized NOPAT Margin		 29.56% 36.73% 60.55% -136.19% -190.26% 0.00% -33.47% -75.76% -250.45% -18.58%
Pre Tax Income Margin		 35.03% 44.04% 71.36% -184.24% -673.53% 0.00% -66.80% -99.13% -376.57% -1,125.14%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -1.99 -4.98 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -1.38 -2.84 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -1.99 -4.98 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -1.38 -2.84 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 7.04% 353.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 7.04% 382.93% -3.75% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Akso Health Group

No quarterly metrics and ratios for Akso Health Group are available.


Financials Breakdown Chart

Frequently Asked Questions About Akso Health Group's Financials

When does Akso Health Group's fiscal year end?

According to the most recent income statement we have on file, Akso Health Group's financial year ends in March. Their financial year 2025 ended on March 31, 2025.

How has Akso Health Group's net income changed over the last 9 years?

Akso Health Group's net income appears to be on an upward trend, with a most recent value of -$135.47 million in 2025, falling from $3.54 million in 2016. The previous period was -$9.52 million in 2024. View Akso Health Group's forecast to see where analysts expect Akso Health Group to go next.

What is Akso Health Group's operating income?
Akso Health Group's total operating income in 2025 was -$166.30 million, based on the following breakdown:
  • Total Gross Profit: -$281.53 thousand
  • Total Operating Expenses: $166.02 million
How has Akso Health Group's revenue changed over the last 9 years?

Over the last 9 years, Akso Health Group's total revenue changed from $11.89 million in 2016 to $14.78 million in 2025, a change of 24.2%.

How much debt does Akso Health Group have?

Akso Health Group's total liabilities were at $15.80 million at the end of 2025, a 339.7% increase from 2024, and a 224.0% increase since 2017.

How much cash does Akso Health Group have?

In the past 8 years, Akso Health Group's cash and equivalents has ranged from $6.67 million in 2020 to $176.23 million in 2025, and is currently $176.23 million as of their latest financial filing in 2025.

How has Akso Health Group's book value per share changed over the last 9 years?

Over the last 9 years, Akso Health Group's book value per share changed from 0.00 in 2016 to 0.46 in 2025, a change of 45.6%.


Related Companies

Financial statements for NASDAQ:AHG last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel